455 related articles for article (PubMed ID: 18827492)
21. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma.
Falk MS; Truitt AK; Coakley FV; Kashani-Sabet M; Hawkins RA; Franc B
Nucl Med Commun; 2007 Apr; 28(4):273-80. PubMed ID: 17325590
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation on non invasive diagnostic tests for the second look in epithelial ovarian cancer].
García Enguídanos A; Crespo Azanza E; Díaz Recaséns J; Lobo Samper F; Jorge Herrero JA; Sáinz de la Cuesta Abbad R
Rev Clin Esp; 1998 Aug; 198(8):502-5. PubMed ID: 9774878
[TBL] [Abstract][Full Text] [Related]
23. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
[TBL] [Abstract][Full Text] [Related]
24. Management of local recurrence of colorectal cancer: the role of PET/CT.
Bamba Y; Itabashi M; Kameoka S
Abdom Imaging; 2011 Jun; 36(3):322-6. PubMed ID: 20661560
[TBL] [Abstract][Full Text] [Related]
25. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography.
Malone JP; Gerberi MA; Vasireddy S; Hughes LF; Rao K; Shevlin B; Kuhn M; Collette D; Tennenhouse J; Robbins KT
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1119-25. PubMed ID: 19917925
[TBL] [Abstract][Full Text] [Related]
26. Role of FDG PET/CT in staging of recurrent ovarian cancer.
Son H; Khan SM; Rahaman J; Cameron KL; Prasad-Hayes M; Chuang L; Machac J; Heiba S; Kostakoglu L
Radiographics; 2011; 31(2):569-83. PubMed ID: 21415197
[TBL] [Abstract][Full Text] [Related]
27. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT.
Wildi SM; Gubler C; Hany T; Petrowsky H; Clavien PA; Jochum W; Gerlach T; Fried M; Mullhaupt B
J Clin Ultrasound; 2008 Jan; 36(1):20-6. PubMed ID: 17937421
[TBL] [Abstract][Full Text] [Related]
28. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
29. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
[TBL] [Abstract][Full Text] [Related]
30. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
[TBL] [Abstract][Full Text] [Related]
31. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
[TBL] [Abstract][Full Text] [Related]
32. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of combined FDG-PET with CT or tumour markers in lung cancer diagnosis.
Kley K; Oehr P
Anticancer Res; 2010 May; 30(5):1741-5. PubMed ID: 20592372
[TBL] [Abstract][Full Text] [Related]
34. The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer.
Kato H; Kimura H; Nakajima M; Sakai M; Sano A; Tanaka N; Inose T; Faried A; Saito K; Ieta K; Sohda M; Fukai Y; Miyazaki T; Masuda N; Fukuchi M; Ojima H; Tsukada K; Oriuchi N; Endo K; Kuwano H
Oncol Rep; 2008 Oct; 20(4):857-62. PubMed ID: 18813827
[TBL] [Abstract][Full Text] [Related]
35. [Role of PET-CT with 18-FDG in the management of UADT squamous-cell carcinomas: a retrospective study of 43 cases].
Ricard AS; Gindre A; Laurentjoye M; Fernandez P; Guyot M; Demeaux H; Siberchicot F; Majoufre-Lefebvre C
Rev Stomatol Chir Maxillofac; 2008 Apr; 109(2):86-90. PubMed ID: 18207477
[TBL] [Abstract][Full Text] [Related]
36. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.
Groheux D; Moretti JL; Baillet G; Espie M; Giacchetti S; Hindie E; Hennequin C; Vilcoq JR; Cuvier C; Toubert ME; Filmont JE; Sarandi F; Misset JL
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):695-704. PubMed ID: 18436392
[TBL] [Abstract][Full Text] [Related]
37. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer.
Yoshida Y; Kurokawa T; Kawahara K; Tsuchida T; Okazawa H; Fujibayashi Y; Yonekura Y; Kotsuji F
AJR Am J Roentgenol; 2004 Jan; 182(1):227-33. PubMed ID: 14684544
[TBL] [Abstract][Full Text] [Related]
38. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
[TBL] [Abstract][Full Text] [Related]
39. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
Gallamini A; Rigacci L; Merli F; Nassi L; Bosi A; Capodanno I; Luminari S; Vitolo U; Sancetta R; Iannitto E; Trentin L; Stelitano C; Tavera S; Biggi A; Castagnoli A; Versari A; Gregianin M; Pelosi E; Torchio P; Levis A
Haematologica; 2006 Apr; 91(4):475-81. PubMed ID: 16585014
[TBL] [Abstract][Full Text] [Related]
40. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
Hutchings M; Loft A; Hansen M; Pedersen LM; Berthelsen AK; Keiding S; D'Amore F; Boesen AM; Roemer L; Specht L
Haematologica; 2006 Apr; 91(4):482-9. PubMed ID: 16585015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
